HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alpha adrenergic blockers in the treatment of benign hyperplasia of the prostate.

Abstract
Benign prostatic hyperplasia (BPH), a common benign tumor in men has been attributed to age and male androgen functions. Of the various management options for treatment of BPH, medical therapy is the first line treatment modality involving either blockade of alpha adrenergic receptors or inhibition of 5-alpha reductase. Amongst these, the alpha-1 blockers are used most frequently. The association of numerous adverse effects with non selective and short acting alpha-1 blockers (like phenoxybenzamine, prazosin and alfuzosin) has led to the development of long acting alpha-1 adrenoceptor blockers (doxazosin, terazosin, tamulosin) which being uroselective significantly reduce the incidence of cardiovascular side effects and increase patient compliance. The review gives a brief account of pharmacological properties and efficacy of alpha adrenergic receptor blockers in the treatment of BPH.
AuthorsV L Kumar, S Dewan
JournalInternational urology and nephrology (Int Urol Nephrol) Vol. 32 Issue 1 Pg. 67-71 ( 2000) ISSN: 0301-1623 [Print] Netherlands
PMID11057776 (Publication Type: Journal Article, Review)
Chemical References
  • Adrenergic alpha-Antagonists
  • Receptors, Adrenergic, alpha
Topics
  • Adrenergic alpha-Antagonists (therapeutic use)
  • Drug Therapy, Combination
  • Humans
  • Male
  • Prostatic Hyperplasia (drug therapy)
  • Receptors, Adrenergic, alpha (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: